Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) on August 25 updated its list of medicines currently under safety risk review, flagging severe gastritis and esophagitis with nine immune checkpoint inhibitors — a move that could eventually result in label revisions…
To read the full story
Related Article
REGULATORY
- MHLW Eyes Bigger Push for Regional Formularies in FY2030–FY2035 Cost Plan
November 18, 2026
- Japan Approves Boey, Wider Labels for Hernexeos, Rinvoq, Tukysa, Pluvicto, and More
November 17, 2026
- Novartis Sjögren’s Drug, Meiji Antibiotic and More Up for Nov. 30 Panel Review
November 17, 2026
- Japan Grants Orphan Status to Rusfertide, Surovatamig, and Lots More
November 17, 2026
- Japan Extends Re-Examination for Saphnelo, Airwin, Fabhalta, Uplizna
November 17, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





